Journals / Türk Patoloji Dergisi / 2010 / Cilt: 26 - Sayı: 1

PAK-1 expression in pancreatic ductal adenocarcinoma: A tissue microarray study

Pankreasın duktal adenokarsinomlarında PAK-1 ekspresyonu: Bir doku mikroarray çalışması

Pages
7–13
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Cases with significant PAK-1 expression had a much better overall survival (median 24 months) compared to those with moderate and minimal expression (median 7 months) (Chi-square=41.07, p=0.001).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: PAK-1, a member of p21-activated serine/threonine protein kinases family, plays an important role in regulating cell motility and invasiveness.
📊
Key Findings & Data:To our knowledge, it has not been investigated in pancreatic ductal adenocarcinoma (PDA) yet.Material and Method: Expression level of PAK-1 was tested in a set of tissue microarray containing 98 cases of PDA.
💡
Conclusion & Impact:Cases with significant PAK-1 expression had a much better overall survival (median 24 months) compared to those with moderate and minimal expression (median 7 months) (Chi-square=41.07, p=0.001).
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: PAK-1, a member of p21-activated serine/threonine protein kinases family, plays an important role in regulating cell motility and invasiveness. To our knowledge, it has not been investigated in pancreatic ductal adenocarcinoma (PDA) yet.Material and Method: Expression level of PAK-1 was tested in a set of tissue microarray containing 98 cases of PDA. Based on the degree of expression level (calculated by an established scoring system incorporating the extent and the intensity of labeling), cases were assigned to one of 4 categories: 0-none, 1-minimal, 2-moderate, and 3-significant. Expression levels were correlated with clinicopathologic features, prognostic parameters, survival, the archival data on K-ras mutation (PCR) and DPC4, p53, p21, p27 and Her2/neu.Results: PAK-1 had a weak expression in ducts and acini while the islets were not stained. In PDAs, 35, 42, and 21 cases had significant, moderate and minimal expression, respectively. The expression had a strong inverse correlation with tumor grade (p=0.04). Cases with significant PAK-1 expression had a much better overall survival (median 24 months) compared to those with moderate and minimal expression (median 7 months) (Chi-square=41.07, p=0.001). Cox Proportional-Hazards Regression Analysis showed that PAK- 1 expression was independently correlated with better survival (p=0.0001). PAK-1 expression also had a strong correlation with DPC4 expression (p=0.035). No significant association with K-ras, p53, p21, p27 or Her2/neu was found.Conclusion: In contrast to breast and colorectal cancers, PAK-1 expression seems to be a good prognostic factor in PDA. Correlation of PAK-1 and DPC4 expression, suggests that PAK-1 expression may be associated with TGF-β signaling and has a different role in PDA compared to breast and colorectal cancers. Further studies are needed to explore the role of PAK-1 in PDA.

Özet

Amaç: p21 ile aktive olan serin/treonin protein kinaz ailesinin bir üyesi olan PAK-1 molekülü hücre motilitesinin ve invazyon yeteneğinin düzenlenmesindeki önemli faktörlerdendir. Bildiğimiz kadarıyla, literatürde pankreasın duktal adenokarsinomlarındaki (PDA) rolü hakkında yapılmış bir çalışma yoktur.Gereç ve Yöntem: PAK-1 ekspresyonu, 98 PDA olgusu içeren bir doku mikroarray setinde test edildi. Ekspresyonun derecesine (boyanma oranını ve şiddetini değerlendiren bir skorlama sistemi ile belirlendi) göre olgular 4 gruba ayrıldı: 0 - Boyanmayan, 1 - minimal boyanan, 2 - orta dereceli boyanan, 3 - güçlü boyanan. Grupların PDA'nın klinikopatolojik özellikleriyle, bilinen prognostik parametreleriyle, sağkalım süresiyle, K-ras mutasyonunun varlığı (PCR) ve DPC4, p53, p21, p27 ve Her2/neu ekspresyonlarının derecesi ile ilişkisine bakıldı.Bulgular: Duktus ve asinüsler PAK-1 ile minimal boyanırken, endokrin adacıklarında boyanma görülmedi. PDA'larda sırasıyla 35, 42 ve 21 olguda güçlü, orta dereceli ve minimal boyanma izlendi. PAK-1 ekspresyonu ile tümör derecesi arasında anlamlı bir ters korelasyon vardı (p=0,04, rho=-0,201). Güçlü PAK-1 boyanması gösteren olguların yaşam sürelerinin (medyan 24 ay) orta dereceli ve minimal boyanan olgularınkine (medyan 7 ay) göre daha iyi olduğu görüldü (Ki-Kare=41,07, p=0,001). Cox Proportional-Hazards regresyon analizi de PAK-1 ekspresyonunun sağkalım süresini diğer değişkenlerden bağımsız olarak olumlu yönde etkilediğini gösterdi (p=0,0001). PAK-1 boyanması ile DPC4 boyanması arasında da anlamlı bir korelasyon vardı (p=0,035). K-ras, p53, p21, p27 ya da Her2/neu ekspresyonu ile anlamlı bir korelasyon saptanmadı.Sonuç: PAK-1 ekspresyonu, meme ve kolorektal kanserlerinin aksine, PDA'lar için iyi prognostik faktör olarak görünmektedir. PAK-1 ekspresyonu ve DPC4 ekspresyonu arasındaki korelasyon ise PAK- 1'in pankreasta TGF-β sinyal yolu ile ilişkili olabileceğini ve bu yüzden PDA gelişiminde meme ve kolorektal kanserlerdekinden farklı bir rol oynayabileceğini düşündürmektedir. PAK-1'in PDA'lardaki rolünün ortaya konabilmesi için ek çalışmalar gerekmektedir.

🔖

Cite This Article

BAŞTÜRK, O., ADSAY, N. V., ALPER, M., LEVİ, E., ÇOBAN, İ. (2022). PAK-1 expression in pancreatic ductal adenocarcinoma: A tissue microarray study. Türk Patoloji Dergisi, Cilt: 26 - Sayı: 1, 7–13. https://ajindex.com/articles/640793

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Balasenthil S, Sahin AA, Barnes CJ, Wang RA, Pestell RG, Vadlamudi RK, Kumar R: p21-activated kinase-1 signaling mediates cyclin D1 expression in mammary epithelial and cancer cells. J Biol Chem 2004, 279:1422-1428 [ PubMed ] 2) Kuhlmann KF, de Castro SM, Wesseling JG, ten Kate FJ, Offerhaus GJ, Busch OR, van Gulik TM, Obertop H, Gouma DJ: Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients. Eur J Cancer 2004, 40:549- 558 [ PubMed ] 3) Kumar R, Gururaj AE, Barnes CJ: p21-activated kinases in cancer. Nat Rev Cancer 2006, 6:459-471 [ PubMed ] 4) Knaus UG, Morris S, Dong HJ, Chernoff J, Bokoch GM: Regulation of human leukocyte p21-activated kinases through G protein-coupled receptors. Science 1995, 269:221-223 [ PubMed ] 5) Gururaj A, Barnes CJ, Vadlamudi RK, Kumar R: Regulation of phosphoglucomutase 1 phosphorylation and activity by a signaling kinase. Oncogene 2004, 23:8118-8127 [ PubMed ] 6) Shalom-Barak T, Knaus UG: A p21-activated kinase-controlled metabolic switch up-regulates phagocyte NADPH oxidase. J Biol Chem 2002, 277:40659-40665 [ PubMed ] 7) Schürmann A, Mooney AF, Sanders LC, Sells MA, Wang HG, Reed JC, Bokoch GM: p21-activated kinase 1 phosphorylates the death agonist bad and protects cells from apoptosis. Mol Cell Biol, 2000, 20:453-461 [ PubMed ] 8) Frost JA, Swantek JL, Stippec S, Yin MJ, Gaynor R, Cobb MH: Stimulation of NFkappa B activity by multiple signaling pathways requires PAK1. J Biol Chem 2000, 275:19693-19699 [ PubMed ] 9) Grooteclaes ML, Frisch SM: Evidence for a function of CtBP in epithelial gene regulation and anoikis. Oncogene 2000, 19:3823- 3828 [ PubMed ] 10) Yang Z, Rayala S, Nguyen D, Vadlamudi RK, Chen S, Kumar R: Pak1 phosphorylation of snail, a master regulator of epithelial-tomesenchyme transition, modulates snail's subcellular localization and functions. Cancer Res 2005, 65:3179-3184 [ PubMed ] 11) Dummler B, Ohshiro K, Kumar R, Field J: Pak protein kinases and their role in cancer. Cancer Metastasis Rev 2009, 28:51-63 [ PubMed ] 12) Edwards DC, Sanders LC, Bokoch GM, Gill GN: Activation of LIM-kinase by Pak1 couples Rac/Cdc42 GTPase signalling to actin cytoskeletal dynamics. Nat Cell Biol 1999, 1:253-259 [ PubMed ] 13) Vadlamudi RK, Bagheri-Yarmand R, Yang Z, Balasenthil S, Nguyen D, Sahin AA, den Hollander P, Kumar R: Dynein light chain 1, a p21-activated kinase 1 interacting substrate, promotes cancerous phenotypes. Cancer Cell 2004, 5:575-585 [ PubMed ] 14) Ra